Category Archives: MS Treatment

Contact Information Available for logged-in reporters only Late Breaker Presentations Late Breaker Abstracts LB1.1 Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis J Cohen1, DL Arnold2,3, G Comi4, A Bar-Or5, S Gujrathi6, JP Hartung6, A Olson6, M Cravets6, PA Frohna6, K Selmaj7 1Cleveland Clinic, Mellen Center for MS Treatment and Research, Cleveland, OH, United States, 2NeuroRx Research, Montreal, QC, Canada, 3McGill University, Montreal, QC, Canada, 4San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Neurology, Milan, Italy, 5Montreal Neurological Institute, Department of Neurology and Neurosurgery, Montreal, QC, Canada, 6Receptos, Inc., Clinical Development, San Diego, CA, United States, 7Medical University of Lodz, Department of Neurology, Lodz, Poland Background: RPC1063 is an oral, selective sphingosine 1-phosphate 1 receptor modulator in clinical development for the treatment of relapsing multiple sclerosis (RMS). Objectives: Demonstrate the superior efficacy of low (LD, 0.5 mg) and high (HD, 1.0 mg) dose RPC1063 vs. placebo (PBO), and characterize the safety of RPC1063 in patients with RMS. Methods: RADIANCE is an international, combined Phase 2/3 trial. In the 24-week, Phase 2 portion, 258 patients were randomized (1:1:1) to PBO (n=88), LD (n=87) or HD (n=83). The primary endpoint was … Continue reading →

Contact Information Available for logged-in reporters only Newswise Boston, Massachusetts, September 9, 2014 On September 10-13 at the Hynes Convention Center in Boston, MA, ACTRIMS-ECTRIMS will host their joint triennial international meeting MSBoston 2014, with over 8,000 participant from leading organizations in Europe, North America and other regions of the world convening to share, discuss and advance research in Multiple Sclerosis (MS). The meeting program will include topics as diverse as the underlying cause of MS, new emerging treatments and repair of the nervous system. MSBoston 2014 will provide journalists with an opportunity to hear about the latest advances in MS, speak with the leading experts, and interact with people living with MS who are also playing a major role in changing the perception of MS and enhancing understanding of this disease. ACTRIMS and ECTRIMS Steering Committee members will be available daily to media for overarching commentary on research in MS, new trends, latest study findings and new developments. Assistance will be available to reporters seeking to speak with specific presenters and experts on-site. The Scientific Program has a diverse program covering many different topics including platform presentations such as: THURSDAY, 11 SEPTEMBER Approaching the cause of multiple sclerosis, D. … Continue reading →

OAK BROOK, Ill. (PRWEB) September 09, 2014 People with multiple sclerosis (MS) lose myelin in the gray matter of their brains and the loss is closely correlated with the severity of the disease, according to a new magnetic resonance imaging (MRI) study. Researchers said the findings could have important applications in clinical trials and treatment monitoring. The study appears online in the journal Radiology. Loss of myelin, the fatty protective sheath around nerve fibers, is a characteristic of MS, an inflammatory disease of the central nervous system that can lead to a variety of serious neurological symptoms and disability. MS is typically considered a disease of the brains signal-conducting white matter, where myelin is most abundant, but myelin is also present in smaller amounts in gray matter, the brains information processing center that is made up primarily of nerve cell bodies. Though the myelin content in gray matter is small, it is still extremely important to proper function, as it enables protection of thin nerve fibers connecting neighboring areas of the brain cortex, according to Vasily L. Yarnykh, Ph.D., associate professor in the Department of Radiology at University of Washington in Seattle. The fact that MS patients lose myelin not … Continue reading →

Opexa initiated preclinical development activities for OPX-212, its drug development candidate for NMO, earlier this year and has achieved several regulatory and early development milestones to date. These include conducting a pre-IND meeting with the FDA and performing in-house manufacturing runs with NMO patient samples. The Company is continuing with preclinical development activities with a goal of filing an IND with the FDA by mid-2015 and then moving into clinical development with a Phase 1/2 proof-of-concept study. The Company believes OPX-212 will qualify for Orphan drug designation and plans also to apply for Fast Track designation for OPX-212. We are pleased to announce our development activities in a second indication utilizing our novel T-cell technology platform, said Neil K. Warma, President and Chief Executive Officer of Opexa. NMO is a disease with a significant unmet medical need. We believe our approach to the treatment of NMO with OPX-212 is highly differentiated as we are directly targeting the T-cell component of the disease and, therefore, addressing the root cause. We believe part of the value of our Precision ImmunotherapyTM T-cell platform comes from the ability to move relatively quickly and cost effectively into new autoimmune diseases. We do not expect our … Continue reading →

Sept. 7, 2014, 9:03 p.m. SISTERS BEACH, TAS: WHEN Kirk Dicker was diagnosed with motor neurone disease, he and his partner Jo Sharp had no idea about the disease. SPREADING THE WORD: Encouraging people to continue with the Ice Bucket Challenge and donate to motor neurone disease research are (from left) Jo Sharp, Kirk Dicker and the couples son Anthony, 4. Picture: Meg Windram. WHEN Kirk Dicker was diagnosed with motor neurone disease, he and his partner Jo Sharp had no idea about the disease. On June 12, they received the news, unsure of what it meant, Ms Sharp researched MND, discovering it was a terminal disease with no cure and no treatment. "I cried for three days and we still do cry because it's still fresh," Ms Sharp said. The Sisters Beach couple wanted the North-West Coast to fully understand the importance of the Ice Bucket Challenge. "People are getting sick of the Ice Bucket Challenge, but do they really know what it is about?" Ms Sharp asked. Mr Dicker's muscle has started wasting away, beginning at his limbs. He requires special apparatus that are fitted to his feet and calves to ensure he can walk, and he struggles … Continue reading →

August 14, 2014 - Womens Health and MS- Self Aspects, Nutrition and Symptoms August 14, 2014 - Women's Health and MS - Self Aspects, Nutrition and Discussion on the Symptoms (two speakers at August 14th program - Patricia spoke first)... By: MSViewsandNews … Continue reading →

MS sufferers could soon be able to "switch off" their illness following a potential medical breakthrough from researchers at the University of Bristol - a result which could improve the lives of 2.5 million people worldwide. The findings could affect a range of autoimmune diseases such as multiple sclerosis (MS), type 1 diabetes, Graves' disease and systemic lupus erythematosus. In their research, published today in Nature Communications, the team reveal how to stop cells from attacking healthy body tissue. The team discovered how cells convert from being aggressive to protecting against disease, rather than the body's immune system destroying its own tissue by mistake. It is hoped the insight will lead to the widespread use of antigen-specific immunotherapy as treatment for many autoimmune disorders. Professor David Wraith, of the university's School of Cellular and Molecular Medicine, led the "exciting" research - which was funded by the Wellcome Trust. "Insight into the molecular basis of antigen-specific immunotherapy opens up exciting new opportunities to enhance the selectivity of the approach while providing valuable markers with which to measure effective treatment," Professor Wraith said. "These findings have important implications for the many patients suffering from autoimmune conditions that are currently difficult to treat." … Continue reading →

Team at Bristol University have described their work as a 'breakthrough' Discovered a way to stop cells from attacking healthy body tissue Conditions which could benefit include MS and type 1 diabetes By Lizzie Parry for MailOnline Published: 05:42 EST, 3 September 2014 | Updated: 08:10 EST, 3 September 2014 2k shares 26 View comments Scientists believe they have discovered how to 'switch off' autoimmune diseases, prompting hope the breakthrough could pave the way for a new treatment for multiple sclerosis. Researchers at the University of Bristol, who describe the work as an 'important breakthrough', say it could improve the lives of millions around the world. The study reveals how to stop cells from attacking healthy body tissue. The team discovered how cells convert from being aggressive to protecting against disease, rather than the body's immune system destroying its own tissue by mistake. Read more from the original source: Breakthrough hope for MS treatment as scientists discover how to 'switch off' autoimmune diseases … Continue reading →

Multiple Sclerosis Signs and Symptoms - New http://www.autoimmunedisease101.com/relapsing-remitting-ms-symptoms-what-you-need-to-know.html Multiple Sclerosis Signs and Symptoms, Ms Treatment On The Doctors, what causes ms signs of multiple... By: Am@zing … Continue reading →

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, President and Chief Executive Officer, will present at two upcoming industry conferences. Details regarding these events are as follows: Rodman & Renshaw 16thAnnual Healthcare Conference Aegis Capital Corp. 2014 Healthcare & Technology Conference About Opexa Opexas mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees and shareholders. The Companys leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from a patients peripheral blood, expanded ex vivo, and reintroduced into the patient via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. About Multiple Sclerosis (MS) MS is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include … Continue reading →